Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in CIS has been growing steadily over the years, driven by various factors that have influenced the market.
Customer preferences: The customers in CIS prefer non-steroidal anti-inflammatory drugs (NSAIDs) due to their effectiveness in reducing inflammation and pain. Additionally, the preference for biologics has been increasing due to their specificity in targeting the immune system.
Trends in the market: There has been a growing trend towards the development of biosimilars, which are less expensive alternatives to biologic drugs. The increased availability of biosimilars has led to a decrease in the price of biologics, making them more accessible to patients. Another trend is the increasing use of combination therapy, where two or more drugs are used together to achieve better results.
Local special circumstances: The healthcare system in CIS is undergoing reforms, with an increasing focus on the provision of quality care to patients. This has led to an increase in the availability of healthcare services, including the availability of drugs. Additionally, there is an increasing prevalence of rheumatic diseases in the region, which has contributed to the growth of the market.
Underlying macroeconomic factors: The economic growth in CIS has been slow, with many countries in the region facing economic challenges. This has led to a decrease in the purchasing power of consumers, which has affected the market. However, the increasing availability of healthcare services and the focus on the provision of quality care has helped to mitigate the impact of the economic challenges.In conclusion, the Anti-Rheumatic Drugs market in CIS is growing steadily, driven by customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. The market is expected to continue growing in the coming years, as healthcare services become more accessible and the prevalence of rheumatic diseases increases.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
